2013年6月
Revelation in the neuroprotective functions of rasagiline and selegiline: the induction of distinct genes by different mechanisms
EXPERT REVIEW OF NEUROTHERAPEUTICS
- ,
- ,
- 巻
- 13
- 号
- 6
- 開始ページ
- 671
- 終了ページ
- 684
- 記述言語
- 英語
- 掲載種別
- DOI
- 10.1586/ERN.13.60
- 出版者・発行元
- EXPERT REVIEWS
In Parkinson's disease, cell death of dopamine neurons in the substantia nigra progresses and neuroprotective therapy is required to halt neuronal loss. In cellular and animal models, selegiline [(-) deprenyl] and rasagiline, inhibitors of type B monoamine oxidase (MAO)-B, protect neuronal cells from programmed cell death. In this paper, the authors review their recent results on the molecular mechanisms by which MAO inhibitors prevent the cell death through the induction of antiapoptotic, prosurvival genes. MAO-A mediates the induction of antiapoptotic bcl-2 and mao-a itself by rasagiline, whereas a different mechanism is associated with selegiline. Rasagiline and selegiline preferentially increase GDNF and BDNF in nonhuman primates and Parkinsonian patients, respectively. Enhanced neurotrophic factors might be applicable to monitor the neurorescuing activity of neuroprotection.
- リンク情報
- ID情報
-
- DOI : 10.1586/ERN.13.60
- ISSN : 1473-7175
- PubMed ID : 23739004
- Web of Science ID : WOS:000319972000014